The European Medicines Agency has accepted Amgen/Onyx’ marketing authorisation application for Kyprolis (carfilzomib) as a treatment for multiple myeloma.

The companies are hoping to get approval for the injection as a treatment for patients with relapsed MM who have received at least one prior therapy.

The agency said it will undertake an accelerated assessment of the drug, which already holds orphan drug status in the region.

For more details, go to: http://www.pharmatimes.com/Article/15-02-26/EMA_will_review_Amgen_Onyx_myeloma_drug.aspx